Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-31 @ 9:50 PM
Study NCT ID:
NCT05087394
Status:
COMPLETED
Last Update Posted:
2023-01-13
First Post:
2021-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
COVID19 Hospitilized in Clinica Pasteur of Neuquen (Argentina)
Sponsor:
Asociacion Latinoamericana de Torax
Organization:
Study Overview
Official Title:
Cohort of COVID19 Patients Admitted to Pasteur Clinic 2020-2021
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVIDPas
Brief Summary:
retrospective cohort (non-experimental study) of COVID 19 patients assisted in hospitalization (severe and critical) between 2020 and 2021
Detailed Description:
Consecutive patients with acute infection by SARS-COV2 and severe or critical COVID19 disease, or acute complications, hospitalized in the Pasteur Clinic of Neuquén city from the beginning of the pandemic in the region until December 31, 2021. Data were obtained retrospectively from information registered simultaneously with hospitalization in three databases (RedCap, DataTech and Excel).
. Inclusion criteria
* Adult patients (over 18 years old)
* Suffering from acute infection by SARS-Cov2, diagnosed by PCR-real time, detection of viral antigen, specific antibodies with or clinical epidemiological criteria
* Hospitalized defined by attending physicians or referral (severe or critical according to NIH) Exclusion criteria
* Patients under 18 years of age.
* Convalescent from acute SARS-Cov2 infection and without evidence of a new event of reinfection.
* Outpatient management or hospitalization less than 24 hours for diagnosis and / or evaluation of severity or complications. Sample Selection Method First patient was registered at the beginning of the pandemic in the region March 20, 2020) and is expected to recruit the las patient diagnosed in December 31, 2021.
The recruitment is consecutive without other selection criteria.
. Inclusion criteria
* Adult patients (over 18 years old)
* Suffering from acute infection by SARS-Cov2, diagnosed by PCR-real time, detection of viral antigen, specific antibodies with or clinical epidemiological criteria
* Hospitalized defined by attending physicians or referral (severe or critical according to NIH) Exclusion criteria
* Patients under 18 years of age.
* Convalescent from acute SARS-Cov2 infection and without evidence of a new event of reinfection.
* Outpatient management or hospitalization less than 24 hours for diagnosis and / or evaluation of severity or complications. Sample Selection Method First patient was registered at the beginning of the pandemic in the region March 20, 2020) and is expected to recruit the las patient diagnosed in December 31, 2021.
The recruitment is consecutive without other selection criteria.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: